Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-377202 in hormone refractory prostate cancer
NCT00987753Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 1999
- Primary completion
- Sep 2000
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin prodrug L-377202 in prostate cancer (PCa), sponsored by University of Alabama at Birmingham. Primary endpoints: Maximally Tolerated Dose, Safety and Tolerability of L-377202 and 1 more. Started Mar 1999; status: completed.
02
Drugs
doxorubicin prodrug L-377202
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00987753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00987753.